ArticleCommunications chemistry2025
Nickel-catalyzed β-arylation and benzylation of 2'-hydroxychalcones to access warfarin analogues.
Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The development of new methods for forming carbon-carbon bonds is essential for advancing the synthesis of biologically active molecules. Achieving high selectivity in these reactions remains a significant challenge in organic chemistry. Here we show that a nickel-catalyzed β-arylation and benzylation of 2'-hydroxychalcones enables the efficient synthesis of chalcone derivatives. This transformation is directed by the substrate's intrinsic hydroxy group, resulting in high chemoselectivity and avoiding unwanted byproducts. The resulting chalcone derivatives can be converted in one step into a series of 3-functionalized 4-hydroxycoumarin compounds. These compounds demonstrate excellent anticoagulant effects in animal studies, with some showing greater activity than the widely used drug warfarin. This approach offers a promising strategy for developing therapeutic agents and functional materials based on the chalcone structure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.